S Walusimbi1,2, I Najjingo2, S Zawedde-Muyanja1, J Musaazi1, A Nyombi3, W Katagira2, J Ssendiwala4, W Muttamba2. 1. Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. 2. Makerere University Lung Institute, College of Health Sciences, Kampala, Uganda. 3. National Tuberculosis and Leprosy Programme, Ministry of Health, Kampala, Uganda. 4. Makerere University School of Public Health Monitoring and Evaluation Technical Support (METS) Program Uganda, Kampala, Uganda.
Abstract
SETTING: Since 2012, Uganda expanded the Xpert® MTB/RIF network for diagnosis of TB. OBJECTIVES: We compared TB care cascades at health facilities with on-site Xpert vs. facilities that accessed the assay through specimen referral. DESIGN: We analysed secondary aggregate data of the National TB and Leprosy Program (NTLP) from 2016 to 2019. We computed the proportions of notified TB cases and mortality ratios in relation to the estimated TB burden. RESULTS: TB case notifications per annum increased from 24,287 in 2016 to 30,739 in 2019, and the proportion of cases diagnosed at facilities with on-site Xpert testing increased from 62% (15,070/24,287) to 81% (24,829/30,739) (P < 0.001). TB mortality at facilities with on-site Xpert decreased from 8.6% (1,302/15,070) to 7.8% (1,938/24,829) (P = 0.41), while it increased at facilities without on-site Xpert from 6.9% (638/9,217) to 8.8% (521/5,910) (P = 0.23). Furthermore, mortality among TB-HIV co-infected patients at facilities with on-site Xpert dropped from 5.0% (760/15,070) in 2016 to 4.8% (1,187/24,826) in 2019 (P = 0.84) compared to 4.4% (407/9,217) in 2016 to 5.3% (315/5,910) in 2019 (P = 0.57). CONCLUSION: Wider installation and decentralisation of Xpert leads to increased case-finding. However, the impact on reduction in mortality remains limited. Interventions to address TB-related mortality in addition to Xpert roll-out are required.
SETTING: Since 2012, Uganda expanded the Xpert® MTB/RIF network for diagnosis of TB. OBJECTIVES: We compared TB care cascades at health facilities with on-site Xpert vs. facilities that accessed the assay through specimen referral. DESIGN: We analysed secondary aggregate data of the National TB and Leprosy Program (NTLP) from 2016 to 2019. We computed the proportions of notified TB cases and mortality ratios in relation to the estimated TB burden. RESULTS: TB case notifications per annum increased from 24,287 in 2016 to 30,739 in 2019, and the proportion of cases diagnosed at facilities with on-site Xpert testing increased from 62% (15,070/24,287) to 81% (24,829/30,739) (P < 0.001). TB mortality at facilities with on-site Xpert decreased from 8.6% (1,302/15,070) to 7.8% (1,938/24,829) (P = 0.41), while it increased at facilities without on-site Xpert from 6.9% (638/9,217) to 8.8% (521/5,910) (P = 0.23). Furthermore, mortality among TB-HIV co-infected patients at facilities with on-site Xpert dropped from 5.0% (760/15,070) in 2016 to 4.8% (1,187/24,826) in 2019 (P = 0.84) compared to 4.4% (407/9,217) in 2016 to 5.3% (315/5,910) in 2019 (P = 0.57). CONCLUSION: Wider installation and decentralisation of Xpert leads to increased case-finding. However, the impact on reduction in mortality remains limited. Interventions to address TB-related mortality in addition to Xpert roll-out are required.
Authors: T Agizew; R Boyd; A F Auld; L Payton; S L Pals; P Lekone; V Chihota; A Finlay Journal: Int J Tuberc Lung Dis Date: 2019-01-01 Impact factor: 2.373
Authors: F M R Perrin; N Woodward; P P J Phillips; T D McHugh; A J Nunn; M C I Lipman; S H Gillespie Journal: Int J Tuberc Lung Dis Date: 2010-12 Impact factor: 2.373
Authors: Talemwa Nalugwa; Priya B Shete; Mariam Nantale; Katherine Farr; Christopher Ojok; Emma Ochom; Frank Mugabe; Moses Joloba; David W Dowdy; David A J Moore; J Lucian Davis; Adithya Cattamanchi; Achilles Katamba Journal: BMC Health Serv Res Date: 2020-03-04 Impact factor: 2.655
Authors: Gian Luca Di Tanna; Ali Raza Khaki; Grant Theron; Kerrigan McCarthy; Helen Cox; Lucy Mupfumi; Anete Trajman; Lynn Sodai Zijenah; Peter Mason; Tsitsi Bandason; Betina Durovni; Wilbert Bara; Michael Hoelscher; Petra Clowes; Chacha Mangu; Duncan Chanda; Alexander Pym; Peter Mwaba; Frank Cobelens; Mark P Nicol; Keertan Dheda; Gavin Churchyard; Katherine Fielding; John Z Metcalfe Journal: Lancet Glob Health Date: 2019-02 Impact factor: 26.763